These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7934607)

  • 41. The role of Helicobacter pylori in peptic ulcer disease.
    O'Connor HJ
    Scand J Gastroenterol Suppl; 1994; 201():11-5. PubMed ID: 8047817
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report.
    Gasbarrini G; Malfertheiner P; Deltenre M; Mégraud F; O'Morain C; Pajares-García J; Quina M; Bianchi Porro G; Gasbarrini A; Franceschi F; Armuzzi A; Cammarota G; Anti M; Pretolani S
    Ital J Gastroenterol Hepatol; 1998 Oct; 30 Suppl 3():S244-7. PubMed ID: 10077746
    [No Abstract]   [Full Text] [Related]  

  • 43. [Effectiveness, safety, and costs of measures for prevention of gastropathy due to the use of nonsteroidal antiinflammatory drugs].
    Salentijn GJ
    Ned Tijdschr Geneeskd; 1999 Nov; 143(46):2340. PubMed ID: 10589227
    [No Abstract]   [Full Text] [Related]  

  • 44. [Antibiotic resistance of Helicobacter pylori in an infectious disease referral center].
    López-Vidal Y; Sigfrido Rangel-Frausto M; Calva JJ
    Rev Invest Clin; 1998; 50(1):19-24. PubMed ID: 9608785
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycinresistant and- sensitive cases.
    Aydin A; Onder GF; Akarca US; Tekin F; Tunçyürek M; Musoğlu A
    Turk J Gastroenterol; 2005 Dec; 16(4):203-6. PubMed ID: 16547848
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparison of the effectiveness of tri- and quadricomponent eradication therapy in patients with peptic ulcer].
    Butorov IV; Osoianu IuP; Butorov SI; Maksimov VV
    Klin Med (Mosk); 2005; 83(12):50-3. PubMed ID: 16502725
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of a new bismuth-free triple therapy in nude mice and humans.
    Karita M; Tsuda M; Okita K; Sugiyama T; Nakazawa T
    Eur J Gastroenterol Hepatol; 1995 Aug; 7 Suppl 1():S31-4. PubMed ID: 8574732
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Diagnosis and therapy of Helicobacter pylori infection. Guidelines of the German Society of Digestive and Metabolic Diseases. Working Group of the German Society of Digestive and Metabolic Diseases].
    Caspary WF; Arnold R; Bayerdörffer E; Behrens R; Birkner B; Braden B; Domschke W; Labenz J; Koletzko S; Malfertheiner P; Menge H; Rösch W; Schepp W; Strauch M; Stolte M
    Leber Magen Darm; 1996 Nov; 26(6):301-4, 307-9. PubMed ID: 9082111
    [No Abstract]   [Full Text] [Related]  

  • 49. [Helicobacter pylori eradication: finally clarity].
    Labenz J
    Leber Magen Darm; 1996 Nov; 26(6):282-3. PubMed ID: 9082109
    [No Abstract]   [Full Text] [Related]  

  • 50. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
    Vakil N; Fennerty MB
    Am J Gastroenterol; 1996 Feb; 91(2):239-45. PubMed ID: 8607487
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Helicobacter pylori and peptic ulcer disease. Reexamining the therapeutic approach.
    Fedotin MS
    Postgrad Med; 1993 Sep; 94(3):38-40, 43-5. PubMed ID: 8361941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Peptic ulcer disease: defining the treatment strategies in the era of Helicobacter pylori.
    Hunt RH
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):36S-40S; discussion 40S-43S. PubMed ID: 9127625
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain).
    Tefera S; Berstad A; Bang CJ; Nysaeter G; Hatlebakk JG; Olafsson S; Nesje LB; Hausken T; Berstad K; Hundal O
    Am J Gastroenterol; 1996 May; 91(5):935-41. PubMed ID: 8633584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. How to treat Helicobacter pylori. First-line, second-line, and future therapies.
    Mégraud F; Marshall BJ
    Gastroenterol Clin North Am; 2000 Dec; 29(4):759-73, vii. PubMed ID: 11190062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Re-eradication of Helicobacter pylori infection following initial treatment failure: treatment options in clinical practice.
    Moshkowitz M; Halpern Z
    Isr Med Assoc J; 2003 Mar; 5(3):193-4. PubMed ID: 12725141
    [No Abstract]   [Full Text] [Related]  

  • 56. [Methods for increasing the efficacy and safety of Helicobacter pylori eradication regimens].
    Zakharova NV
    Eksp Klin Gastroenterol; 2006; (4):59-66. PubMed ID: 17269426
    [No Abstract]   [Full Text] [Related]  

  • 57. [One week triple therapy for eradication of Helicobacter pylori infection: simple and effective].
    Diehl HG
    Leber Magen Darm; 1995 Dec; 25(6):283. PubMed ID: 8577220
    [No Abstract]   [Full Text] [Related]  

  • 58. [Good results with Helicobacter pylori eradication for treatment of non-ulcer dyspepsia].
    Bock H; Mares A
    Leber Magen Darm; 1996 Sep; 26(5):268. PubMed ID: 9005302
    [No Abstract]   [Full Text] [Related]  

  • 59. [Helicobacter pylori-induced cost-benefit risk considerations].
    Leiss O
    Leber Magen Darm; 1989 Dec; 19(6):333-5. PubMed ID: 2575693
    [No Abstract]   [Full Text] [Related]  

  • 60. On: The who's and when's of therapy for Helicobacter pylori.
    Burette A; Glupczynski Y
    Am J Gastroenterol; 1991 Jul; 86(7):924-5. PubMed ID: 2058644
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.